CRIS Current Research Information System

POERIO, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.151
EU - Europa 963
AS - Asia 571
AF - Africa 76
SA - Sud America 5
Totale 2.766
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.145
GB - Regno Unito 251
SE - Svezia 169
CN - Cina 161
VN - Vietnam 137
DE - Germania 112
IT - Italia 103
SG - Singapore 98
JP - Giappone 73
UA - Ucraina 64
NL - Olanda 58
FR - Francia 52
IN - India 45
RU - Federazione Russa 38
IE - Irlanda 34
TG - Togo 33
HK - Hong Kong 26
CI - Costa d'Avorio 22
CH - Svizzera 16
EE - Estonia 14
FI - Finlandia 14
JO - Giordania 14
ZA - Sudafrica 14
BG - Bulgaria 11
BE - Belgio 10
GR - Grecia 8
CA - Canada 6
IR - Iran 6
BR - Brasile 4
SC - Seychelles 4
NG - Nigeria 3
TR - Turchia 3
AT - Austria 2
BD - Bangladesh 2
ES - Italia 2
KR - Corea 2
PH - Filippine 2
CL - Cile 1
CZ - Repubblica Ceca 1
ID - Indonesia 1
LB - Libano 1
LT - Lituania 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 2.766
Salva come PNG Salva come JPEG
Città #
Southend 216
Chandler 180
Fairfield 108
Ashburn 92
Singapore 81
Woodbridge 70
Tokyo 65
Houston 61
Dong Ket 59
Wilmington 59
Seattle 57
Ann Arbor 56
Jacksonville 44
Princeton 39
Cambridge 35
Dublin 34
Lomé 33
Santa Clara 28
Boardman 25
Hong Kong 25
Abidjan 22
Turin 22
Falls Church 20
Nanjing 20
Westminster 19
New York 18
Padova 18
Amman 14
Bern 14
Helsinki 14
Falkenstein 12
Jinan 12
Berlin 11
Sofia 11
Brussels 10
Hefei 10
Beijing 9
Saint Petersburg 8
Jiaxing 7
Milan 7
Nanchang 7
San Diego 7
Taizhou 7
Shenyang 6
Bremen 5
Des Moines 5
Guangzhou 5
Hangzhou 5
Hebei 5
Medford 5
Munich 5
Pune 5
Tianjin 5
Bologna 4
Changsha 4
Chiyoda-ku 4
Dearborn 4
Florence 4
Frankfurt am Main 4
Mahé 4
Mülheim 4
Washington 4
Zhengzhou 4
Abeokuta 3
Haikou 3
Hamamatsu 3
Hanoi 3
Istanbul 3
San Venanzo 3
Verona 3
Wuhan 3
Yubileyny 3
Bengaluru 2
Bexley 2
Cagliari 2
Cardito 2
Chicago 2
Dhaka 2
Düsseldorf 2
Groningen 2
Harbin 2
Kashan 2
Kunming 2
Lauterbourg 2
Los Angeles 2
Mountain View 2
Ningbo 2
Norwalk 2
Ottawa 2
Phoenix 2
Quận Bình Thạnh 2
Redwood City 2
Riolo Terme 2
Rome 2
San Nicola la Strada 2
Shanghai 2
Stockholm 2
São Paulo 2
Toronto 2
Amsterdam 1
Totale 1.839
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 239
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 230
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 218
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 210
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 186
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 179
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 171
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 143
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 139
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 127
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 127
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 126
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 125
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 119
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 111
null 85
null 77
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis 58
null 57
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome 56
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 50
Totale 2.833
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.916
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.916
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202041 0 0 0 0 0 0 0 0 0 0 0 41
2020/2021346 57 27 5 10 9 12 1 24 38 14 20 129
2021/2022444 51 6 34 46 36 28 9 44 12 29 78 71
2022/2023587 72 116 31 70 36 45 14 24 94 14 50 21
2023/2024211 5 21 5 18 12 90 23 15 2 3 12 5
2024/2025439 13 56 32 36 58 38 27 19 1 65 25 69
Totale 2.833